drugset / Trial / NCT03674203

Efficacy of Platelet-rich Plasma in Treatment of Melasma

NCT03674203

Phase 2 Completed 20 enrolled Mexican Social Security Institute
NaSingle-groupOpen-labelTreatment

Summary

The application of Platelet Rich Plasma (PRP) on three occasions with an interval of 15 days between each one, is related to a decrease in the intensity of the spots and improvement in the quality of the skin of patients with melasma.

Timeline

Start
2017-05-01
Primary completion
2018-05-31
Completion
2018-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Platelet Rich Plasma Other / unclassified 1 ml Other